The Unseen Struggle: A Comprehensive Clinical Review of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis
By Dr. Agatha Bis
Introduction: The Forgotten Joint in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of autoimmune diseases, representing the most common chronic rheumatologic condition of childhood. It is defined by the presence of synovial inflammation that begins before the age of 16 and persists for a minimum of six weeks.¹ This condition can manifest in any synovial joint within the body, leading to a cascade of symptoms including pain, stiffness, swelling, and functional limitation. However, among the many joints susceptible to this autoimmune attack, the temporomandibular joint (TMJ), the complex ginglymoarthrodial joint responsible for connecting the mandible to the skull, presents a unique and particularly formidable clinical challenge.¹
Historically, the TMJ has been grossly overlooked in the field of pediatric rheumatology, often earning it the label of the "forgotten joint" despite its frequent and significant involvement in the disease process.⁵ This clinical oversight is detrimental. The TMJ is not merely a hinge; it is a critical center for craniofacial growth and is integral to fundamental daily functions such as mastication and speech. Inflammation within this joint during the crucial developmental years of childhood and adolescence can have devastating and irreversible consequences, ranging from severe facial deformities to profound functional impairment.
This report will argue that the insidious and frequently asymptomatic nature of TMJ arthritis in JIA creates a dangerous disconnect between underlying disease activity and overt clinical presentation. This disconnect is the primary driver of high rates of delayed diagnosis, which in turn leads to the development of irreversible dentofacial deformities and a significant reduction in quality of life. The evidence presented will demonstrate that a fundamental shift in clinical practice is urgently required. The current paradigm, which is often reactive and symptom-based, must be replaced by a proactive, imaging-led screening protocol for all children diagnosed with JIA. Such a shift is essential to mitigate long-term morbidity, preserve function, and improve the lifelong outcomes for this vulnerable patient population.
Epidemiology and Pathophysiology of TMJ Involvement
Prevalence of TMJ Arthritis in JIA: A Wide and Telling Spectrum
The medical literature reports a strikingly broad prevalence of TMJ involvement in children with JIA, with estimates ranging from as low as 10–17% to as high as 80–96%.⁷ This vast discrepancy is not a reflection of true epidemiological variance but is instead a direct consequence of profound methodological inconsistencies across different research studies. Key factors contributing to this wide range include the use of non-standardized diagnostic criteria, the reliance on different imaging modalities with varying sensitivities, and the analysis of heterogeneous patient cohorts.⁷ The variability itself serves as a powerful indicator of a systemic failure within the field to adopt uniform and sensitive diagnostic protocols.
A clear pattern emerges when analyzing the data: studies that rely solely on clinical signs and patient-reported symptoms consistently report lower prevalence figures. For example, one large cohort study identified clinical TMJ involvement in only 11.6% of over 3,300 children with JIA.¹² In stark contrast, studies that employ advanced imaging techniques, particularly contrast-enhanced magnetic resonance imaging (CE-MRI), reveal a much higher, and likely more accurate, prevalence of active synovitis.¹³ Research using MRI has documented evidence of TMJ arthritis in 43% to 75% of JIA patients, often affecting all disease subtypes.¹³ This suggests that the lower end of the reported prevalence range represents a significant underestimation rooted in the use of insensitive clinical examinations, while the upper end of the range reveals the true, silent burden of the disease that is only unmasked by advanced imaging. Consequently, it is highly probable that a substantial number of children with JIA have undiagnosed, active TMJ arthritis.
To illustrate this critical point, the following table synthesizes data from various studies, highlighting the direct correlation between the diagnostic method used and the reported prevalence of TMJ involvement.
| First Author / Year | Country / Region | Number of Patients | Diagnostic Method(s) Used | Reported Prevalence (%) | Key Notes |
|---|---|---|---|---|---|
| Frid P, et al. (2017) 12 | International | 3,343 | Clinical Examination | 11.6% | Large cohort study highlighting the low rate of clinically apparent disease. |
| Alqanatish JT, et al. (2021) 1 | Saudi Arabia | 123 | Clinical and/or MRI | 16% | Retrospective review from a single institute. |
| Cannizzaro E, et al. (2011) 17 | Not Specified | 223 | Clinical and/or Radiological | 38.6% | Single-center cohort with a mean follow-up of 4.6 years. |
| Twilt M, et al. (2004) 19 | Not Specified | 97 | Orthodontic Evaluation, OPG | 45% | Focused on orthodontic evaluation and radiographic changes. |
| K. Tzaribachev, et al. (2023) 7 | Not Specified | 41 | Contrast-Enhanced MRI | 52.8% | Small, single-center study using the gold standard imaging method. |
| Weiss PF, et al. (2008) 13 | USA | 32 | MRI | 75% | Prospective study of new-onset JIA patients, revealing very high prevalence at diagnosis. |
| Various Sources 10 | General Literature Review | N/A | Mixed (Clinical, Imaging) | Up to 80–96% | Reviews summarizing the highest reported rates, typically from MRI-based studies. |
Stratification by JIA Subtype: Identifying High-Risk Populations
The risk of TMJ involvement is not uniformly distributed across the seven distinct subtypes of JIA as defined by the International League of Associations for Rheumatology (ILAR).³ A clear and consistent pattern emerges from the data, indicating that patients who develop a polyarticular disease course, defined by the involvement of five or more joints in the first six months of disease, are at a significantly higher risk.⁷ This is a critical clinical observation, as it allows for risk stratification and targeted surveillance of the most vulnerable patient populations.
While specific prevalence rates vary between studies, the relative risk associated with each subtype remains largely consistent. The highest rates of TMJ arthritis are consistently found in patients with extended oligoarticular JIA and rheumatoid factor (RF)-negative polyarticular JIA. Conversely, patients with enthesitis-related arthritis (ERA; ERA is a form of juvenile idiopathic arthritis affecting children, characterized by both arthritis, where joint pain and swelling both exist, and enthesitis, which is inflammation where tendons and ligaments attach to bone) consistently demonstrate the lowest risk of TMJ involvement. This stratification is essential for clinical decision-making, providing an evidence-based framework for prioritizing screening efforts.
| JIA Subtype | Reported Prevalence Range (%) | Key Studies (Citations) | Associated Risk Level |
|---|---|---|---|
| Extended Oligoarticular | 61% | 17 | High |
| RF-Negative Polyarticular | 52–59% | 17 | High |
| Psoriatic Arthritis | 33–50% | 17 | Moderate to High |
| Systemic Onset JIA (SOJIA) | 36–67% | 17 | Moderate to High |
| RF-Positive Polyarticular | 33% | 17 | Moderate |
| Persistent Oligoarticular | 33–39% | 17 | Moderate |
| Enthesitis-Related Arthritis (ERA) | 11–13% | 17 | Low |
Unique Vulnerability of the Mandibular Condyle
The pathophysiology of TMJ damage in JIA is intrinsically linked to the unique and vulnerable anatomy of the growing mandible. The primary growth center of the mandible is located within the condylar head, a structure that is separated from the synovial space of the joint by only a thin layer of fibrocartilage.⁵ This anatomical proximity is the root of the problem. Unlike in larger peripheral joints where the growth plates are more distant from the synovium, any inflammatory process within the TMJ can directly and immediately affect the delicate growth plate.⁴
The inflammatory cascade characteristic of JIA, involving an influx of immune cells and pro-inflammatory cytokines, disrupts the normal processes of chondrocyte function and endochondral ossification within the condyle. This leads to impaired, asymmetric, or even completely arrested mandibular growth.⁵ This destructive process is particularly damaging in younger children, as the most intense and critical period of mandibular growth occurs within the first six years of life. During this time, the mandible is highly susceptible to inflammatory insults, and any disruption can lead to profound and permanent deformities.⁴ Furthermore, there is evidence to suggest that the TMJ may possess a unique immunological microenvironment. Studies comparing gene expression in the synovium of the TMJ to that of the ankle joint in arthritis models have found that the TMJ exhibits increased expression of genes associated with energy consumption and bone resorption-related enzymes.²² This biological distinction could help explain the clinical observation that TMJs often appear to respond less well to standard systemic therapies that are effective for other joints, suggesting a heightened intrinsic susceptibility to arthritis-related damage.⁶
Key Risk Factors for TMJ Involvement: A Predictive Clinical Profile
Beyond the JIA subtype, a constellation of specific clinical and serological markers helps to construct a more detailed profile of the high-risk patient, allowing for more targeted and proactive clinical surveillance. The combination of these factors creates a powerful predictive model that can guide screening decisions. A patient presenting with a younger age at JIA diagnosis, a polyarticular disease course, a longer disease duration, and co-existing arthritis in the cervical spine represents a "highest-risk" phenotype that warrants immediate and intensive screening, regardless of the presence or absence of orofacial symptoms.
The key identified risk factors include:
Disease Course: A polyarticular course, regardless of the onset subtype, is one of the most significant determinants of TMJ involvement.⁷
Age at Onset: A younger age at the initial diagnosis of JIA is consistently and strongly associated with a higher likelihood of developing TMJ arthritis.¹³
Disease Duration: A longer duration of active disease is a significant risk factor for the development and progression of TMJ involvement.⁷
Co-existing Arthritis: The involvement of the cervical spine is a particularly powerful predictor, with one study reporting an odds ratio of 4.6 for TMJ involvement in patients with cervical spine arthritis.⁹ The involvement of other upper extremity joints is also associated with an increased risk.¹⁷
Serological Markers: The presence of antinuclear antibodies (ANA) is frequently cited as a risk factor for TMJ involvement.¹ Conversely, the presence of the human leukocyte antigen (HLA)-B27 marker appears to be protective, which aligns with the consistently lower prevalence of TMJ arthritis observed in the ERA subtype, where HLA-B27 is common.¹
Inflammatory Markers: A higher erythrocyte sedimentation rate (ESR) at the time of JIA diagnosis has also been identified as a factor associated with an increased risk of developing TMJ arthritis.¹⁷
The Diagnostic Conundrum: Why TMJ Arthritis is Frequently Missed
The Challenge of the Asymptomatic Patient: A Clinically Silent Disease
The single greatest barrier to the timely diagnosis and treatment of TMJ arthritis in children with JIA is the overwhelmingly asymptomatic nature of the disease in its early stages. Multiple independent studies have consistently reported that a staggering 65% to 85% of children with radiologically confirmed active inflammation in their TMJs have no subjective symptoms, such as pain, clicking, or stiffness.⁷ This clinical silence is profoundly misleading. Pain, when it does eventually manifest, is typically a late indicator, often appearing only after significant and irreversible structural damage to the joint has already occurred.¹⁰ The complete absence of pain does not correlate with the absence of active, destructive synovitis, creating a critical and dangerous silent window during which the inflammatory process can progress unchecked, leading to the erosion of the mandibular condyle and the disruption of normal facial growth.⁸
This phenomenon creates a significant cognitive bias in clinical practice. The term "asymptomatic" is often misinterpreted as indicating a benign or inactive state, leading to a "watchful waiting" approach that delays intervention during the most critical period for preventing long-term damage. This creates a false sense of security for clinicians, parents, and patients alike. To combat this clinical inertia, the paradigm must shift. The condition should not be thought of as "asymptomatic" but rather as "clinically silent" or “subclinical,” terms that more accurately imply an active but hidden disease process that requires proactive investigation, rather than a harmless state that requires no action. This reframing is essential to underscore the urgent need for screening based on risk factors, not on the presence of symptoms.
Limitations of the Physical Examination: An Unreliable Indicator
Compounding the problem of clinical silence is the poor diagnostic accuracy of the standard physical examination. Both rheumatological and orthodontic clinical assessments have proven to be unreliable indicators for detecting early-stage TMJ arthritis. Key clinical signs that are often screened for, such as pain on palpation, crepitation (a grating sound or sensation), and asymmetry during jaw excursion, demonstrate high specificity but critically low sensitivity.⁷ This means that while the presence of these signs strongly suggests a problem, their absence provides no reassurance that the joint is healthy.
The statistical evidence for this limitation is compelling. One study that compared clinical examination methods to the gold standard of MRI found that rheumatological, orthodontic, and ultrasound examinations correctly diagnosed only 58%, 47%, and 33% of patients with active arthritis, respectively. This translates to a staggering misdiagnosis rate of 42%, 53%, and 67% for these respective methods.¹⁴ Another prospective study found that patient-reported symptoms of TMJ pain and dysfunction were only 26% sensitive for identifying MRI-confirmed arthritis.¹⁰ A systematic review concluded that no single physical exam finding could accurately predict the presence of TMJ inflammation on an MRI. This profound discrepancy between clinical signs and the actual presence of active arthritis leads to the unequivocal conclusion that a medical history and physical examination, when used alone, are insufficient and inadequate for screening for TMJ disease in children with JIA.¹³ The lack of standardized examination techniques and formal screening protocols across different medical centres further exacerbates this diagnostic challenge, leading to inconsistent and often delayed care.¹¹
The Crucial Role of Advanced Imaging
Given the failure of clinical evaluation to reliably detect early disease, imaging plays a paramount and indispensable role in the diagnosis and management of TMJ arthritis in JIA.¹⁵ The current state of TMJ screening, however, represents a significant gap between evidence and practice. Despite overwhelming evidence for the insufficiency of clinical exams and the clear superiority of MRI, screening practices in many centres remain highly variable and often rely on the least sensitive methods, such as conventional radiography.²⁰ This points to systemic barriers that must be addressed, including the cost and accessibility of MRI, a lack of pediatric radiology expertise in interpreting TMJ images, and the urgent need for updated clinical practice guidelines that mandate imaging-based screening for high-risk patients.
Contrast-Enhanced MRI (CE-MRI): The Gold Standard
Contrast-enhanced Magnetic Resonance Imaging is universally considered the gold standard for the diagnosis of TMJ arthritis in JIA.⁶ Its superiority lies in its unique ability to visualize soft tissues with exceptional detail. This allows for the direct detection of the earliest signs of active inflammation, including synovial thickening (synovitis), joint effusion (excess fluid), and bone marrow edema within the mandibular condyle. These findings are often present long before any structural bony changes become visible on other imaging modalities.¹⁵ The use of gadolinium contrast (a contrast agent used in MRI scans to enhance the visibility of internal organs, tumors, and blood vessels by shortening proton relaxation times) is critical, as it highlights areas of active inflammation by demonstrating synovial enhancement, which is often the earliest and most common finding of TMJ arthritis in children with JIA.²⁷ Early detection via CE-MRI can prompt specific and aggressive therapy, with the hope of preventing the progression to destructive and irreversible disease.²⁷
Comparative Analysis of Other Modalities
While CE-MRI is the gold standard, other imaging modalities have specific, albeit more limited, roles in the evaluation of the TMJ in JIA. It is crucial for clinicians to understand the strengths and weaknesses of each to ensure their appropriate application.
Conventional Radiography (X-ray/Orthopantomogram – OPG): These methods are widely available and involve low radiation exposure. However, they possess very low sensitivity for detecting early inflammatory changes. They are only capable of visualizing late-stage, chronic damage, such as condylar erosion, alterations in condylar morphology, and established growth disturbances.²⁰ While an OPG may have some value as a low-cost screening tool for identifying significant, established bony changes, it will unequivocally miss early, active disease and should not be used to rule out TMJ arthritis.⁴
Computed Tomography (CT) and Cone-Beam CT (CBCT): These modalities provide excellent, high-resolution visualization of osseous structures and are far superior to conventional radiography for assessing the precise extent of structural damage, such as erosions, cysts, and condylar deformities.⁴ CBCT, in particular, offers this detail with a lower radiation dose than traditional CT. However, the primary limitation of both CT and CBCT is their inability to visualize soft tissue inflammation. They cannot detect active synovitis and are therefore not suited for the early diagnosis of active disease. Their main role is in the assessment of structural damage for orthodontic or surgical planning once chronic disease is established.⁴
Ultrasound (US): While ultrasound is a valuable tool for assessing synovitis in more accessible peripheral joints like the knee or wrist, its utility in evaluating the TMJ is severely limited. The overlying bony structures, particularly the zygomatic arch, create an acoustic shadow that prevents a complete and reliable visualization of the joint space. Studies have shown that ultrasound has poor performance in detecting MRI-proven inflammation in the TMJ and is therefore not recommended as a primary screening tool.¹⁴
The following table provides a practical decision-making guide for clinicians, clearly outlining the appropriate use of each imaging modality for specific clinical questions related to TMJ arthritis in JIA.
| Modality | Primary Target Tissue | Key Findings Detected | Strengths | Limitations | Recommended Clinical Use |
|---|---|---|---|---|---|
| Contrast-Enhanced MRI (CE-MRI) | Soft Tissue & Bone Marrow | Synovitis, joint effusion, bone marrow edema, pannus formation, disc deformity, early erosions | Highest sensitivity for active inflammation; no ionizing radiation | High cost, limited availability, may require sedation in young children | Gold standard for early diagnosis of active arthritis and for monitoring treatment response. |
| CT / Cone-Beam CT (CBCT) | Bone | Erosions, condylar flattening, osteophytes, cysts, detailed 3D morphology | Excellent high-resolution visualization of bony structures; lower radiation with CBCT | Cannot visualize soft-tissue inflammation; ionizing radiation | Assessment of extent of chronic structural damage; pre-surgical planning. |
| Ultrasound (US) | Soft Tissue (limited) | Can sometimes detect effusions | Non-invasive, no radiation, low cost | Overlying bone causes acoustic shadow; poor performance versus MRI for TMJ inflammation | Not recommended as a primary screening tool. |
| Conventional Radiography (X-ray / Orthopantomogram – OPG) | Bone | Late-stage, chronic bony changes (e.g., condylar erosion, altered condylar morphology, established growth disturbances) | Widely available; low radiation exposure | Very low sensitivity for early inflammatory changes | Low-cost screening for established bony changes; will miss early active disease and should not be used to rule out TMJ arthritis. |
The Cascade of Consequences: The Impact of Delayed or Inadequate Treatment
The failure to diagnose and adequately treat TMJ arthritis in a timely manner sets off a cascade of debilitating and often irreversible consequences that profoundly affect a child's physical health, functional ability, and psychosocial well-being. The consequences of this disease create a vicious, self-perpetuating cycle of disability. The initial inflammation causes growth disturbance and pain. This leads to functional limitations, such as altered chewing patterns, which in turn can cause secondary muscle dysfunction and exacerbate abnormal joint loading, leading to further damage. The resulting facial deformity causes significant psychological distress, which can increase parafunctional habits like clenching and heighten pain perception, further worsening the condition. This feedback loop underscores the need for treatment to address all aspects of the cycle, inflammation, function, and psychological well-being to achieve successful outcomes.
Irreversible Dentofacial Deformities
The most visually striking and permanent consequence of untreated TMJ inflammation is the development of severe craniofacial deformities. Because the inflammation directly targets the mandibular growth center, it leads to a disruption of normal facial development that can be extremely difficult to correct later in life.⁴ The nature of the deformity depends on whether the arthritis affects one or both joints:
Bilateral Involvement: When both TMJs are affected, the growth of the entire mandible is stunted. This leads to mandibular retrognathia (a receded chin) and micrognathia (an abnormally small jaw). This combination creates the characteristic "bird-face" appearance, which can be a source of significant psychological distress for the patient.⁵ This skeletal discrepancy also results in a severe dental malocclusion, most notably an anterior open bite, where the front teeth do not meet when the back teeth are closed.⁴
Unilateral Involvement: When only one TMJ is affected, the growth on that side of the jaw is arrested while the unaffected side continues to grow normally. This differential growth leads to a pronounced facial asymmetry, with the chin and lower jaw deviating towards the affected side.⁴
These changes are not merely cosmetic flaws; they represent a fundamental alteration of the facial skeleton. Correcting these deformities often requires complex and invasive interventions later in life, including extensive orthodontic treatment combined with major orthognathic (jaw) surgery.²⁹
Functional Impairment and Systemic Health Issues
The structural damage and ongoing inflammation caused by TMJ arthritis lead to significant and progressive functional disability.²⁰ Patients commonly experience a reduced maximal mouth opening (also known as trismus or lockjaw), which can interfere with eating, speaking, and maintaining oral hygiene.¹² Chewing becomes painful and inefficient, often leading to dietary limitations where patients must avoid hard, chewy, or tough foods. This can have a negative impact on nutrition during critical periods of growth and development.¹²
In the most severe cases of micrognathia, the reduced size of the lower jaw can compromise the upper airway, leading to the development of obstructive sleep apnea. This is a serious systemic health complication characterized by repeated episodes of breathing cessation during sleep, which can have long-term cardiovascular and neurocognitive consequences.¹
Chronic Pain and Reduced Health-Related Quality of Life (HRQOL)
While early-stage TMJ arthritis is often painless, the progression to chronic disease is frequently accompanied by the onset of persistent orofacial pain, chronic headaches, and debilitating morning stiffness in the jaw.⁷ This chronic pain, combined with functional limitations, takes a significant toll on the patient's overall well-being.
Crucially, TMJ involvement appears to act as a "disease multiplier," amplifying the overall burden of JIA. Multiple studies have explicitly demonstrated that JIA patients with TMJ involvement have significantly higher levels of disability, higher overall disease activity scores (as measured by tools like the Juvenile Arthritis Disease Activity Score, or JADAS), and markedly impaired health-related quality of life (HRQOL) when compared to both JIA patients without TMJ involvement and healthy controls.⁴ This suggests that TMJ arthritis is not merely an isolated comorbidity but is either an indicator of a more severe overall disease phenotype or a direct contributor to the patient's global decline. The significant pain, functional limitation, and systemic stress caused by TMJ arthritis may actively worsen the patient's overall condition. Therefore, identifying and effectively treating TMJ arthritis is critical not only for preserving the jaw but also for improving the patient's global JIA control and well-being. The burden of these symptoms is not transient; long-term studies show that they frequently persist into adulthood, leading to a lifetime of challenges.³³
The Psychosocial Toll: The Invisible Scars
The combination of chronic pain, functional limitations, and visible facial deformities has a profound and often devastating psychosocial impact on children and adolescents during their most critical developmental years.³⁵ The daily struggle with a condition that affects their appearance, their ability to eat with friends, and their ability to communicate can lead to significant emotional and psychological distress.
Research has shown that JIA patients with orofacial pain report significantly higher levels of stress, depression, and pain catastrophizing (a negative cognitive and emotional response to pain).³⁵ This emotional burden can manifest as withdrawal from social activities, school avoidance, and feelings of being misunderstood, isolated, or stigmatized by their peers.³⁵ Concerns about body image, stemming directly from facial asymmetry or micrognathia, are a significant issue that can damage self-esteem.³⁸ The impact extends beyond the patient to the entire family unit. Parents often experience immense emotional strain and financial pressure from navigating a complex and chronic medical condition, while the family's daily life can be disrupted by the child's physical limitations and medical needs.³⁴
A Modern, Multidisciplinary Approach to Management
The management of TMJ arthritis in JIA is complex and has undergone a significant evolution in recent years. The recognition of the joint's silent nature and the severe consequences of under-treatment has prompted a shift away from a conservative, stepwise approach towards a more proactive and aggressive management strategy. Effective care is predicated on two core principles: early and aggressive pharmacological intervention to control inflammation, and a coordinated, multidisciplinary team approach to manage the functional and structural sequelae of the disease.
Evolving Pharmacological Strategies: Towards Early, Aggressive Intervention
Recent treatment guidelines, most notably those from the American College of Rheumatology (ACR), represent a paradigm shift in the pharmacological management of JIA. There is now a strong emphasis on the early initiation of disease-modifying antirheumatic drugs (DMARDs) and biologic agents, with a concurrent recommendation to minimize or avoid the long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) and oral corticosteroids. This change is driven by the recognition that while NSAIDs and steroids can provide temporary symptomatic relief, they are largely ineffective at halting the underlying disease process and preventing joint destruction, and they carry a significant burden of potential side effects.³⁹
The current pharmacological armamentarium includes:
NSAIDs: These are conditionally recommended for a brief trial as part of an initial therapy plan, primarily to manage pain and discomfort. However, they should be considered as adjunctive or bridge therapy, not a definitive long-term solution, and treatment should be escalated quickly if a complete response is not achieved.⁴⁰
Intra-articular Corticosteroid Injections (IAGCs): The use of steroid injections directly into the TMJ is now highly controversial and is conditionally recommended against in skeletally immature patients.⁴⁰ While IAGCs are a standard and effective treatment for inflammation in other joints, emerging evidence in the TMJ has raised serious safety concerns. Studies in both animal models and humans suggest that IAGCs can impair mandibular growth and may lead to heterotopic ossification (the formation of bone in soft tissue) within the joint.⁴⁰ This highlights a critical shift in the risk-benefit calculation for the TMJ: the treatment itself can be as harmful as the disease it is meant to control. This forces a re-evaluation of local versus systemic therapy, strongly favouring early and aggressive systemic treatment with biologics to avoid the need for potentially harmful local injections in growing children. IAGCs may still be considered sparingly for symptomatic relief in individuals who are skeletally mature.⁴⁴
Conventional Synthetic DMARDs (csDMARDs): Methotrexate is the first-line csDMARD and is strongly recommended for patients whose disease does not respond adequately to initial therapies. It works by suppressing the overactive immune system and has been shown to minimize TMJ destruction in polyarticular JIA.³⁹
Biologic DMARDs (bDMARDs): These targeted therapies represent the cornerstone of modern treatment for moderate-to-severe or refractory TMJ arthritis. For most JIA subtypes, Tumor Necrosis Factor inhibitors (TNFi) such as adalimumab (sold under brand names such as Humira) and etanercept (sold under brand names such as Enbrel, Brenzys, and Erelzi) are commonly used, often in combination with methotrexate.⁴² Crucially, recent prospective studies have provided the first MRI-based evidence that biologic therapies, specifically TNFi, can significantly reduce TMJ inflammation, improve orofacial symptoms (pain, morning stiffness, mouth opening), and either stabilize or improve joint deformity scores over a 24-month period.⁴⁵ For systemic JIA, which has a different underlying inflammatory pathway, IL-1 and IL-6 inhibitors [e.g., anakinra (an interleukin-1 receptor antagonist), canakinumab (blocks the protein interleukin-1 beta, IL-1β, which drives inflammation), tocilizumab (blocks the activity of IL-6)] are the recommended first-line biologic agents.⁴² The current ACR guidelines explicitly advocate for a "rapid escalation" to a DMARD or biologic for TMJ arthritis, acknowledging its uniquely destructive nature.³⁹
Essential Non-Pharmacological and Interventional Therapies
Pharmacological treatment, while essential for controlling inflammation, is often insufficient on its own. A comprehensive management plan must also address the functional and structural consequences of the disease through a combination of rehabilitative and interventional therapies.
Physical Therapy: Physical therapy is conditionally recommended and plays a vital role in managing the functional aspects of TMJ arthritis. A targeted program of therapeutic exercises and manual therapy can help to improve jaw range of motion, strengthen the muscles of mastication, manage pain, and restore normal function.⁵⁰
Occlusal Splints and Orthopedic Devices: Custom-fabricated oral appliances, or splints, are an important component of management. These devices can help to unload the inflamed joint, reduce pain from muscle hyperactivity, control parafunctional habits like clenching and grinding, and, most importantly in growing children, can be designed to help guide and normalize mandibular growth that has been affected by the arthritis.⁴³
Surgical Interventions: Surgery is generally reserved as a last resort for refractory cases or for patients with end-stage disease who have severe, fixed deformities and significant functional impairment. Surgical options exist on a spectrum, from minimally invasive procedures like arthrocentesis (a joint "wash-out" to remove inflammatory debris) to complex reconstructive surgeries, including orthognathic surgery to correct skeletal deformities or total alloplastic joint replacement for completely destroyed joints.²⁴
The Imperative of an Integrated Care Team
Effective management of the multifaceted challenges posed by JIA-associated TMJ arthritis is impossible within the confines of a single medical specialty. It unequivocally requires a dedicated, integrated, and interdisciplinary team that collaborates closely on diagnosis, treatment planning, and long-term patient follow-up.²⁰
The success of such a team, however, is contingent on more than just having different specialists in the same room. It requires a shared understanding of the disease and a commitment to common, patient-centered goals, which is an area where consensus is still developing.⁶ A rheumatologist's primary goal is to suppress systemic inflammation, while a dentist's primary goal is to optimize facial growth. These goals can sometimes be in conflict. The true innovation of a multidisciplinary team lies in its ability to create a unified treatment plan that balances these competing priorities to achieve the optimal overall outcome for the patient. This requires the development of integrated care pathways and consensus guidelines for the team to follow, ensuring all clinicians are working in concert.
The core members of this integrated care team should include:
A Pediatric Rheumatologist: To manage the systemic autoimmune disease and lead pharmacological treatment.
A Dentist: To monitor and manage craniofacial growth and dentofacial deformities.
Oral Maxillofacial Surgeon: To plan surgical interventions.
A Physical Therapist: To manage pain and restore normal jaw function.
A Radiologist: To provide accurate imaging diagnosis and interpretation.
Additional Specialists: Depending on the patient's specific needs, the team may also include a pediatric dentist, a psychologist to address the psychosocial impact of the disease, and a pain management specialist.³⁸
Prognosis, Long-Term Outcomes, and Future Directions
Long-Term Follow-up: Persistence into Adulthood
TMJ arthritis associated with JIA is not a condition that children simply "grow out of." The damage and dysfunction incurred during childhood often persist, leading to a lifetime of challenges. Long-term follow-up studies that have tracked JIA cohorts into adulthood reveal a high prevalence of ongoing orofacial symptoms, persistent functional limitations, and lasting radiographic damage to the joint.³³
One landmark 17-year follow-up study of a population-based JIA cohort provided a sobering look at these long-term outcomes. The study found that, as young adults, 33% of the JIA patients reported at least one orofacial symptom (such as TMJ pain, morning stiffness, or limitation on chewing), and a striking 61% had evidence of condylar deformities on CBCT imaging.³³ These findings powerfully underscore the chronic nature of the disease and highlight the critical necessity of establishing a system for continued interdisciplinary follow-up that extends into adulthood to manage these persistent issues.
The Potential for Condylar Regeneration
Despite the potential for severe and permanent damage, there is compelling evidence that the mandibular condyle possesses a significant intrinsic capacity for regeneration and remodelling. This healing potential, however, is contingent upon the early and effective control of the underlying inflammation.⁵⁶ This discovery reframes the therapeutic goal beyond simple inflammation control. The objective is not just to halt the destructive process, but to create a biological environment where the body's own healing capacity can be harnessed to reverse existing damage and promote the normalization of growth. This elevates the importance of non-pharmacological treatments, such as functional appliances (properly adjusted) and physical therapy, which may help to guide this regenerative process once the inflammation has been brought under control by systemic medication.
A crucial 5-year follow-up study provided direct evidence of this regenerative potential. The study found that condylar alterations improved in 83% of the initially affected patients, with complete normalization of the condylar shape observed in 44% of those who improved. Critically, this improvement was directly and significantly related to achieving and maintaining a state of low overall disease activity.⁵⁶ This finding provides a strong biological rationale for the modern therapeutic strategy of early, aggressive, systemic treatment aimed at rapidly achieving disease remission.
Addressing Gaps in Research and Clinical Practice
A major and recurring theme throughout the literature on JIA-associated TMJ arthritis is the profound lack of high-level, evidence-based data to guide clinical management. This is a direct consequence of the historical neglect of the TMJ in major JIA research. For decades, the TMJ has been grossly overlooked in large-scale clinical trials for JIA therapeutics, meaning that TMJ-specific outcomes were rarely, if ever, measured.⁵ As a result, most current treatment recommendations, including the 2021 ACR guidelines for TMJ arthritis, are based on low or very low-quality evidence, relying heavily on expert consensus and extrapolation from studies of other joints.²⁴ This is why a majority of the recommendations are designated as "conditional" rather than "strong." This is not merely a research gap; it represents a systemic failure to prioritize a common and highly debilitating aspect of the disease.
To rectify this, a clear and urgent research agenda is needed. The priorities for future research must include:
Development of Standardized Protocols: There is a critical need for the development and validation of standardized, universally accepted protocols for both clinical screening and imaging of the TMJ in JIA. This is essential to ensure consistency in diagnosis and to allow for meaningful comparisons between different research studies.¹¹
Prospective Clinical Trials: High-quality, prospective, randomized controlled trials are desperately needed to compare the efficacy of different biologic agents and treatment strategies specifically for TMJ arthritis. Future JIA drug trials must be mandated to include TMJ-specific clinical and imaging endpoints as part of their core protocols to build the evidence base required for strong, data-driven treatment recommendations.
Longitudinal and Biomarker Studies: Further longitudinal studies are required to better understand the natural history of TMJ disease in the modern biologic era. Additionally, research is needed to identify reliable biomarkers that can help predict which patients are at highest risk, what their disease course will be, and how they will respond to specific therapies.⁶
Pathophysiological Research: A deeper investigation into the unique pathophysiology and immunological microenvironment of the TMJ is needed to pave the way for the development of more targeted and effective therapies.²²
Conclusion: Reframing the Standard of Care for JIA
Temporomandibular joint arthritis is a common, uniquely destructive, and clinically silent complication of Juvenile Idiopathic Arthritis. The evidence synthesized in this report demonstrates that the traditional, symptom-driven, and reactive model of clinical care has proven to be profoundly inadequate, leading to preventable, severe, and lifelong morbidity for a significant number of children. The disconnect between the absence of symptoms and the presence of active, damaging inflammation has allowed this "forgotten joint" to be overlooked for far too long, with devastating consequences for craniofacial development, physical function, and psychosocial well-being.
The current body of evidence overwhelmingly supports a fundamental and urgent paradigm shift in the management of this condition. The standard of care for every child diagnosed with JIA must evolve to include proactive, routine screening for TMJ involvement, a process that should be initiated at the time of diagnosis and continued throughout their care, irrespective of the presence or absence of clinical signs or symptoms. Given its unparalleled sensitivity for detecting the early inflammatory changes that precede irreversible damage, contrast-enhanced MRI must be the cornerstone of this screening strategy, particularly for patients who fall into the well-defined high-risk categories.
However, early diagnosis alone is not enough. It must be coupled with prompt, early, and aggressive systemic therapy, guided by the principles of modern rheumatologic care that prioritize the use of effective biologic agents. This pharmacological intervention must be delivered within the framework of a collaborative, integrated, and multidisciplinary team that can simultaneously address the complex functional, structural, and psychosocial needs of the patient. This proactive and comprehensive approach offers the best, and indeed the only, hope of controlling inflammation, preventing irreversible damage, harnessing the condyle's intrinsic regenerative potential, and ultimately preserving function and quality of life for these vulnerable patients. Continued research, heightened clinical awareness, and the universal adoption of evidence-based screening protocols are paramount to ensuring that the "forgotten joint" is finally given the critical clinical attention it demands and deserves.
Works cited
Temporomandibular joint involvement in children with juvenile idiopathic arthritis, accessed September 20, 2025, https://smj.org.sa/content/42/4/399
Polyarticular juvenile idiopathic arthritis – epidemiology and m | CLEP - Dove Medical Press, accessed September 20, 2025, https://www.dovepress.com/polyarticular-juvenile-idiopathic-arthritis-ndash-epidemiology-and-man-peer-reviewed-fulltext-article-CLEP
Temporomandibular joint involvement in children with juvenile idiopathic arthritis: A single tertiary-center experience - PMC, accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8128629/
Perspective on clinical and imaging tools for early identification of temporomandibular joint involvement in juvenile idiopathic arthritis - Open Exploration Publishing, accessed September 20, 2025, https://www.explorationpub.com/Journals/emd/Article/100785
JIA & the Temporomandibular Joint: Diagnostic Challenges & Treatment Options, accessed September 20, 2025, https://www.the-rheumatologist.org/article/diagnosis-treatment-of-arthritis-in-the-temporomandibular-joint-in-kids/
Contemporary management of TMJ involvement in JIA patients and its orofacial consequences - PMC, accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4890481/
Evaluation of temporomandibular joint involvement in juvenile idiopathic arthritis patients, accessed September 20, 2025, https://www.springermedizin.de/evaluation-of-temporomandibular-joint-involvement-in-juvenile-id/50243878
Evaluation of temporomandibular joint involvement in juvenile idiopathic arthritis patients - PMC, accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11590203/
Temporomandibular Joint Involvement in Juvenile Idiopathic Arthritis: The Results from a Retrospective Cohort Tertial Center Study - MDPI, accessed September 20, 2025, https://www.mdpi.com/2075-1729/13/5/1164
Temporomandibular joint arthritis in juvenile idiopathic arthritis, now ..., accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5918758/
Early diagnosis of temporomandibular joint arthritis in children with juvenile idiopathic arthritis. A systematic review - European Journal of Paediatric Dentistry, accessed September 20, 2025, https://ejpd.eu/EJPD_2020_03_12.pdf
Temporomandibular Joint Involvement in Children With Juvenile Idiopathic Arthritis, accessed September 20, 2025, https://www.medpagetoday.com/resource-centers/advances-rheumatoid-arthritis/temporomandibular-joint-involvement-children-juvenile-idiopathic-arthritis/1796
Temporomandibular joint involvement in children with juvenile idiopathic arthritis, accessed September 20, 2025, https://www.semanticscholar.org/paper/5f1e5dd6e098ff8a7b8fb6536ee388adc0326f83
Early diagnosis of temporomandibular joint involvement in juvenile idiopathic arthritis: a pilot study comparing clinical examination and ultrasound to magnetic resonance imaging - PMC, accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2681286/
MR Imaging of the Temporomandibular Joint in Juvenile Idiopathic Arthritis: Technique and Findings | RadioGraphics - RSNA Journals, accessed September 20, 2025, https://pubs.rsna.org/doi/abs/10.1148/rg.2017160078
Risk Factors for Temporomandibular Joint Arthritis in Children with Juvenile Idiopathic Arthritis | The Journal of Rheumatology, accessed September 20, 2025, https://www.jrheum.org/content/early/2012/05/14/jrheum.111441
Temporomandibular Joint Involvement in Children with Juvenile Idiopathic Arthritis | Request PDF - ResearchGate, accessed September 20, 2025, https://www.researchgate.net/publication/49684921_Temporomandibular_Joint_Involvement_in_Children_with_Juvenile_Idiopathic_Arthritis
Temporomandibular Joint Involvement in Children with Juvenile Idiopathic Arthritis - The Journal of Rheumatology, accessed September 20, 2025, https://www.jrheum.org/content/jrheum/early/2010/12/12/jrheum.100325.full-text.pdf
Temporomandibular involvement in juvenile idiopathic arthritis. | The ..., accessed September 20, 2025, https://www.jrheum.org/content/31/7/1418
The perceived prevalence of TMJ arthritis among the JIA cohorts at the... - ResearchGate, accessed September 20, 2025, https://www.researchgate.net/figure/The-perceived-prevalence-of-TMJ-arthritis-among-the-JIA-cohorts-at-the-various-centers_fig2_259915918
Temporomandibular Joint Involvement in Children with Juvenile Idiopathic Arthritis - CORE, accessed September 20, 2025, https://core.ac.uk/outputs/364007471/?source=2
Prevalence of temporomandibular disorders in juvenile idiopathic ..., accessed September 20, 2025, https://www.researchgate.net/publication/375964503_Prevalence_of_temporomandibular_disorders_in_juvenile_idiopathic_arthritis_evaluated_with_diagnostic_criteria_for_temporomandibular_disorders_A_systematic_review_with_meta-analysis
The Connection Between Juvenile Idiopathic Arthritis and TMJ in Kids - MedCenter TMJ, accessed September 20, 2025, https://www.medcentertmj.com/tmj-disorder-causes-treatments/the-connection-between-juvenile-idiopathic-arthritis-and-tmj-in-kids/
Juvenile Idiopathic Arthritis - The TMJ Association, accessed September 20, 2025, https://tmj.org/living-with-tmj/diagnosis-and-related-conditions/juvenile-idiopathic-arthritis/
In children and adolescents with temporomandibular disorder assembled with juvenile idiopathic arthritis - no association were found between pain and TMJ deformities using CBCT - ProQuest, accessed September 20, 2025, https://search.proquest.com/openview/b8bce34bb43e9e49de4aacd1b46703f0/1?pq-origsite=gscholar&cbl=42535
JIA subtype and frequency of TMJ involvement (n = 97). | Download Table - ResearchGate, accessed September 20, 2025, https://www.researchgate.net/figure/JIA-subtype-and-frequency-of-TMJ-involvement-n-97_tbl1_8478577
Imaging of the Temporomandibular Joint in Juvenile Idiopathic Arthritis - The University of Alabama at Birmingham, accessed September 20, 2025, https://www.uab.edu/medicine/peds/images/Rheum/TMJ_imaging_ACR_2014_Cron.pdf
Early detection of temporomandibular joint arthritis in children with juvenile idiopathic arthritis – the role of contrast-enhanced MRI | Request PDF - ResearchGate, accessed September 20, 2025, https://www.researchgate.net/publication/265176474_Early_detection_of_temporomandibular_joint_arthritis_in_children_with_juvenile_idiopathic_arthritis_-_the_role_of_contrast-enhanced_MRI
Treatment management of children with juvenile idiopathic arthritis with temporomandibular joint involvement: a systematic review - PubMed, accessed September 20, 2025, https://pubmed.ncbi.nlm.nih.gov/24650371/
Treatment management of Children with Juvenile Idiopathic Arthritis with temporomandibular joint involvement: a systematic review | Request PDF - ResearchGate, accessed September 20, 2025, https://www.researchgate.net/publication/260114060_Treatment_management_of_Children_with_Juvenile_Idiopathic_Arthritis_with_temporomandibular_joint_involvement_a_systematic_review
Juvenile Idiopathic Arthritis of the Temporomandibular Joint – no longer the forgotten joint, accessed September 20, 2025, https://www.researchgate.net/publication/350549738_Juvenile_Idiopathic_Arthritis_of_the_Temporomandibular_Joint_-_no_longer_the_forgotten_joint
8 Consequences and Complications of Untreated TMJ Disorders - Stony Brook Dental Group, accessed September 20, 2025, https://www.stonybrookdental.com/8-consequences-and-complications-of-untreated-tmj-disorders/
17 years of follow-up of Nordic Juvenile Idiopathic Arthritis (JIA) cohort. - NTNU Open, accessed September 20, 2025, https://ntnuopen.ntnu.no/ntnu-xmlui/bitstream/handle/11250/2722686/Glerup_Lonterm+outcomes+of+TMJ_2020_postscript.pdf?sequence=2
Unforgivable Injury - The TMJ Association, accessed September 20, 2025, https://tmj.org/living-with-tmj/stigmas-and-related-topics/unforgivable-injury/
Orofacial pain in juvenile idiopathic arthritis is associated with stress as well as psychosocial and functional limitations - DiVA portal, accessed September 20, 2025, https://www.diva-portal.org/smash/get/diva2:1410990/FULLTEXT01.pdf
Orofacial pain in juvenile idiopathic arthritis is associated with stress as well as psychosocial and functional limitations - PMC - PubMed Central, accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6921529/
Temporomandibular Disorders and Juvenile Idiopathic Arthritis: Scoping review with a case report - European Journal of Paediatric Dentistry, accessed September 20, 2025, https://ejpd.eu/EJPD_2020_21_04_09.pdf
Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges - ACR Meeting Abstracts, accessed September 20, 2025, https://acrabstracts.org/abstract/establishing-a-multidisciplinary-registry-for-temporomandibular-joint-arthritis-in-juvenile-idiopathic-arthritis-insights-into-patient-outcomes-and-management-challenges/
Juvenile Idiopathic Arthritis & Systemic JIA Treatments, accessed September 20, 2025, https://www.arthritis.org/health-wellness/treatment/treatment-plan/ja-medical-decisions/treatment-guidelines-for-jia-arthritis-foundation
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis (JIA) - Deep Blue Repositories, accessed September 20, 2025, https://deepblue.lib.umich.edu/bitstream/handle/2027.42/172047/art42037.pdf?sequence=1
The American College of Rheumatology Releases Two Updated Guidelines for Treatment of Juvenile Idiopathic Arthritis, accessed September 20, 2025, https://rheumatology.org/press-releases/the-american-college-of-rheumatology-releases-two-updated-guidelines-for-treatment-of-juvenile-idiopathic-arthritis-
Comprehensive Management of Rheumatic Diseases Affecting the Temporomandibular Joint - MDPI, accessed September 20, 2025, https://www.mdpi.com/2075-4418/11/3/409
What are the treatment options for refractory Temporomandibular Joint (TMJ) disorder?, accessed September 20, 2025, https://www.droracle.ai/articles/260477/treatment-options-for-refractory-tmj-
JIA & the Temporomandibular Joint: Diagnostic Challenges & Treatment Options - Page 3 of 5 - The Rheumatologist, accessed September 20, 2025, https://www.the-rheumatologist.org/article/diagnosis-treatment-of-arthritis-in-the-temporomandibular-joint-in-kids/3/
Juvenile Idiopathic Arthritis: Biologic Treatments Reduce TMJ Inflammation - EMJ, accessed September 20, 2025, https://www.emjreviews.com/rheumatology/news/juvenile-idiopathic-arthritis-biologic-treatments-reduce-tmj-inflammation/
Effects of Biologics on Temporomandibular Joint Inflammation in Juvenile Idiopathic Arthritis, accessed September 20, 2025, https://pubmed.ncbi.nlm.nih.gov/39617412/
Biologics Ease Temporomandibular Joint Inflammation in Juvenile Arthritis - EMJ, accessed September 20, 2025, https://www.emjreviews.com/rheumatology/news/biologics-ease-temporomandibular-joint-inflammation-in-juvenile-arthritis/
2 New Clinical Practice Guidelines for JIA Released - Page 4 of 7 - The Rheumatologist, accessed September 20, 2025, https://www.the-rheumatologist.org/article/two-new-clinical-practice-guidelines-for-jia-released/4/
A narrative review of the management of juvenile idiopathic arthritis - World Health Organization (WHO), accessed September 20, 2025, https://cdn.who.int/media/docs/default-source/essential-medicines/2023-eml-expert-committee/applications-for-addition-of-new-medicines/a3_anakinra_narrative-review-jia.pdf?sfvrsn=ebc1a378_2
Temporomandibular Disorders - Medical Clinical Policy Bulletins - Aetna, accessed September 20, 2025, https://www.aetna.com/cpb/medical/data/1_99/0028.html
Physical Therapy Guide to Juvenile Idiopathic Arthritis - Choose PT, accessed September 20, 2025, https://www.choosept.com/guide/physical-therapy-guide-juvenile-idiopathic-arthritis
Multimodal Approaches in the Management of Temporomandibular Disorders: A Narrative Review - MDPI, accessed September 20, 2025, https://www.mdpi.com/2077-0383/14/12/4326
Splint Therapy vs. Other Therapies to Treat TMJ, accessed September 20, 2025, https://www.tmjtexas.com/splint-therapy-vs-other-therapies-to-treat-tmj
Effects of an Interdisciplinary Approach in the Management of Temporomandibular Disorders: A Scoping Review - MDPI, accessed September 20, 2025, https://www.mdpi.com/1660-4601/20/4/2777
Management of Orofacial Manifestations of Juvenile Idiopathic Arthritis: Interdisciplinary Consensus‐Based Recommendations - PMC, accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10100353/
Long-term followup of temporomandibular joint involvement in juvenile idiopathic arthritis, accessed September 20, 2025, https://pubmed.ncbi.nlm.nih.gov/18383409/
Systemic Treatment for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis - The Journal of Rheumatology, accessed September 20, 2025, https://www.jrheum.org/content/jrheum/47/6/793.full.pdf
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis - PMC, accessed September 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10161784/